Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service thrombectomy, IVC filters & venous stents cases in New Jersey: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 9% on average (194 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 23 | 1,693 | 33% |
| 2020 | 14 | 1,455 | 36% |
| 2021 | 20 | 1,638 | 39% |
| 2022 | 23 | 1,653 | 41% |
| 2023 | 19 | 1,658 | 43% |
| 2024 | 25 | 1,782 | 45% |
| 2025 from claims | – | 1,569 1,440–1,660 | 46% |
| 2026 forecast | – | 1,596 1,404–1,842 | 46% |
| 2027 forecast | – | 1,620 1,385–1,931 | 47% |
| 2028 forecast | – | 1,645 1,372–2,014 | 47% |
| 2029 forecast | – | 1,669 1,363–2,093 | 47% |
| 2030 forecast | – | 1,694 1,357–2,171 | 48% |
Mechanical thrombectomy, IVC filter placement, and iliac venous stenting. Professional codes (what the surgeon bills): CPT 37187, 37184, 37191, 37238.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 63% of the cases CMS names in New Jersey; 17 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 66% inpatient hospital, 6% hospital outpatient, 28% office. The share outside the hospital has moved +17 pts since 2019, so more of this market is decided in surgery centers and offices each year.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 24 | 2,696−2.3%/yr | −2.3%/yr | 1.5 | 17% | 3,720 in 2030+5.5%/yr |
| Pennsylvania | 14 | 1,998+1.6%/yr | +1.6%/yr | 1.5 | 9% | 2,310 in 2030+2.4%/yr |
| Massachusetts | 2 | 738−0.4%/yr | −0.4%/yr | 0.8 | 9% | 740 in 2030+0.1%/yr |
| Connecticut | 1 | 474−5.9%/yr | −5.9%/yr | 1.4 | 23% | 420 in 2030−1.9%/yr |
| New Hampshire | 0 | 145−3.6%/yr | −3.6%/yr | 0.6 | 0% | 220 in 2030+7.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Peripheral arterial intervention | 55 | 8,709+2.3%/yr | +2.3%/yr | 8.01.8× | 77% | 12,700 in 2030+6.4%/yr |
| Dialysis access | 58 | 7,071−13%/yr | −13%/yr | 7.01.3× | 70% | 7,590 in 2030+1.2%/yr |
| Superficial venous ablation | 70 | 4,906−2.3%/yr | −2.3%/yr | 4.51.4× | 97% | 6,260 in 2030+4.1%/yr |
| Carotid revascularization | 26 | 1,073−1.9%/yr | −1.9%/yr | 1.01.0× | 0% | 1,090 in 2030+0.2%/yr |
| Aortic endografts (EVAR/TEVAR) | 3 | 400−7.7%/yr | −7.7%/yr | 0.40.9× | 0% | 360 in 2030−1.6%/yr |
Thrombectomy, IVC filters & venous stents in every state, and its device makers · Every procedure market in New Jersey · Every state · Compare with New York
Penumbra leads with 54% of company spending on these surgeons in 2025, +31 pts on 2024.
In 2025, 15 companies reported engagement with New Jersey’s surgeons worth $222K in consulting, speaking, meals and travel tied to these products, about $8,896 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 22 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.